Treatment sequences and prognostic/predictive factors in metastatic pancreatic ductal adenocarcinoma: univariate and multivariate analyses of a real-world study in Europe

被引：0

作者：

Julien Taieb

Thomas Seufferlein

Michele Reni

Daniel H. Palmer

John A. Bridgewater

Antonio Cubillo

Gerald W. Prager

Alice Vermeire

Fabienne Hédouin-Biville

Zhaoyang Teng

Teresa Macarulla

机构：

[1] Université de Paris,Department of Gastroenterology and Digestive Oncology

[2] Georges Pompidou European Hospital,Department of Internal Medicine I

[3] SIRIC CARPEM,Department of Medicine I

[4] Université Paris-Cité,Vall d´Hebron University Hospital

[5] Hôpital Européen Georges Pompidou,undefined

[6] Hepatogastroenterology and GI Oncology,undefined

[7] University Hospital Ulm,undefined

[8] University Vita E Salute,undefined

[9] IRCCS,undefined

[10] San Raffaele Scientific Institute,undefined

[11] University of Liverpool,undefined

[12] UCL Cancer Institute,undefined

[13] HM CIOCC University Hospital,undefined

[14] Medical University of Vienna,undefined

[15] Servier,undefined

[16] Servier Pharmaceuticals,undefined

[17] Vall d´Hebron Institute of Oncology (VHIO),undefined

[18] IOB Quiron,undefined

来源：

BMC Cancer | / 23卷

关键词：

Pancreatic cancer; Metastatic; Survival; Prognostic factors; Real-world data;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 129 条

[1] Malvezzi M(2014)European cancer mortality predictions for the year 2014 Ann Oncol 25 1650-1656
[2] Bertuccio P(2019)Epidemiology of pancreatic cancer: global trends, etiology and risk factors World J Oncol 10 10-27
[3] Levi F(2015)Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 26 v56-68
[4] La Vecchia C(2016)Cancer treatment and survivorship statistics, 2016 CA Cancer J Clin 66 271-289
[5] Negri E(2020)Pancreatic ductal adenocarcinoma: treatment hurdles, tumor microenvironment and immunotherapy World J Gastrointest Oncol 12 173-181
[6] Rawla P(2014)Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States Cancer Res 74 2913-2921
[7] Sunkara T(2020)How I treat pancreatic cancer ESMO Open 4 10740-10751
[8] Gaduputi V(2014)Borderline resectable pancreatic cancer: definitions and management World J Gastroenterol 20 1817-1825
[9] Ducreux M(2011)FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer N Engl J Med 364 1691-1703
[10] Cuhna AS(2013)Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine N Engl J Med 369 103-105